What is OncoSELECT?

OncoSELECT is a new minimally invasive genomic study that allows detecting mutations present in the circulating tumour DNA from a blood sample and that has three specific panels for patients with lung cancer (NSCLC), colon or breast (RH + or HER2 +).


OncoSELECT is the perfect tool for:

  • Identify therapeutic options in patients in whom the extraction of a biopsy sample is not possible, or in cases in which the amount of sample is insufficient or too old.
  • Detect possible resistance to treatment, even before routine imaging tests.
  • Monitor the tumour response, allowing adapting treatment.

Based on a recent modification of the FDA guidelines, liquid biopsy is now approved as the first diagnostic tool for patients with Non-Small Cell Lung Cancer, so OncoSELECT is the perfect study to perform a first screening the most relevant genes that are related to treatments.

Specific gene panels

OncoSELECT is unique because it focuses only on the targets that have a greater importance in each type of cancer. It is a study focused on essential markers of response or resistance to treatment and is currently available in three versions:

  • Patients with lung cancer (NSCLC)
  • Patients with colorectal cancer (CRC)
  • Patients with breast cancer (RH + or HER2 +)

Genetic panels according to type of cancer


OncoSELECT está indicado en pacientes adultos con tumores sólidos en cáncer de pulmón (NSCLC), cólon o mama (RH+ o HER2+) en los que:

  • Existen múltiples opciones estándar de tratamiento y se quiere elegir la más eficaz
  • Las opciones estándar no pueden ser consideradas debido a las comorbilidades del paciente
  • Se han agotado las líneas de tratamiento estándar
  • El tumor es altamente agresivo
  • El tumor es raro o infrecuente

In partnership with: